Clinical trial results for
previously treated
advanced liver cancer
For adults with a type of liver cancer called hepatocellular carcinoma when your liver cancer cannot be removed by surgery or has spread, and you have received prior treatment with sorafenib
Actor portrayals.
In a clinical trial, the overall response rate and duration of response to OPDIVO + YERVOY were looked at in 49 people with hepatocellular carcinoma whose cancer spread or grew after treatment with sorafenib or who could not tolerate sorafenib therapy.
Tumors disappeared completely (complete response)
Tumors shrank
(partial response)
Tumors shrank or disappeared completely (overall response)
Half of the people who responded to OPDIVO + YERVOY continued to respond for at least 17.5 months, also known as median duration of response. The shortest response lasted 4.6 months and the longest response lasted 30.5 months.
88% of people who responded had a response for six months or longer.
56% of people who responded had a response for 1 year or longer.
31% of people who responded had a response for 2 years or longer.
Words to know
Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.
Partial response is when a tumor reacts to treatment and shrinks.
Complete response is when a tumor reacts to treatment and disappears completely. This is the disappearance of any measurable tumors in response to treatment. This does not mean the cancer has been cured.
Duration of response is the measure of how long these responses lasted. The median duration of response is the length of time half of the patients were still responding to treatment.
OPDIVO + YERVOY will not work for everyone. Individual results may vary.
It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.
See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)
For adults whose liver cancer (hepatocellular carcinoma) has spread or grown after treatment with sorafenib
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with a type of liver cancer called hepatocellular carcinoma (HCC) when your liver cancer cannot be removed by surgery or has spread, and you have received prior treatment with sorafenib.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
As a subcutaneous injection
OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is a prescription medicine used to treat a type of liver cancer called hepatocellular carcinoma (HCC). It is used alone if you have previously received treatment with sorafenib, and after completing combination treatment with intravenous nivolumab and ipilimumab. This use was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO Qvantig for this use.
It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig may not be used in combination with ipilimumab.
